NRC-AN-019
CAS: 879507-25-2
Ref. 3D-EKB50725
| 1mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Product Information
NRC-AN-019 is an imatinib-resistant drug that belongs to the class of bcr-abl inhibitors. It has been shown to be effective in women with metastatic breast cancer and who are resistant to lapatinib and imatinib. NRC-AN-019 is a polymeric matrix that contains epidermal growth factor (EGF) and is designed for topical administration. The drug binds to the receptor tyrosine kinase erbB2, which prevents it from binding with the epidermal growth factor receptor (EGFR). This leads to suppression of cellular proliferation, differentiation, and angiogenesis. NRC-AN-019 also has pharmacokinetic properties that allow for escalation of dosage without significant toxicities or side effects.
Chemical properties
Technical inquiry about: 3D-EKB50725 NRC-AN-019
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
